RGCC – Greek Test

RGCC (Research Genetics Cancer Center) is a global specialist medical genetics company, established in 2004 with headquarters in Switzerland.  According to their web site, they are experts in developing and providing personalized cancer genetics tests for doctors and patients, and testing tumors for sensitivity and resistance to chemotherapy treatment and a range of natural substances.  They say they are actively involved in pharmaceutical research and development, using the most technologically advanced equipment and specialized software for data analysis.

RGCC divides their work into two main sectors:

  • Testing services, which detect tumors that are sensitive and resistant to chemotherapy treatment using microarray technology.
  • Analytical services, which includes detecting, immunophenotyping and isolating circulating tumor cells, using flow cytometers.

The main goal of RGCC tests is to discover, analyze and screen the cancer cells in every step of the disease. Their tests are designed to: detect potential early signs of undetected cancers, monitor existing diagnosed cancers, and produce personalized guidance on which chemotherapy drugs and natural treatments could benefit individual patients.

I cannot remember where I heard about this test. It is talked about in many alternative circles. The one appointment that I had with my independent oncologist, I mentioned this test. He dismissed it as hogwash. All I have to say, is that most oncologists dismiss nutrition as hogwash also.

I find the test fascinating. And if it can isolate circulating cancer cells and determine the agents that work best on that cancer, then we are better off.

I did my first RGCC test blood draw on February 19, 2018. For more information, see this blog post.

Sources